Target intelligence / Profile preview

Lipid A phosphate group divalent cation binding site

Molecular classification
Bacterial outer membrane component, Lipopolysaccharide component, Glycolipid, Other
01

Overview

The divalent cation binding sites on lipid A phosphate groups are essential structural components of the Gram-negative bacterial outer membrane [1]. These sites consist of negatively charged phosphate moieties located at the 1 and 4' positions of the lipid A anchor of lipopolysaccharide (LPS) [2]. Divalent cations, primarily magnesium (Mg2+) and calcium (Ca2+), bind to these phosphate groups to form ionic bridges that cross-link adjacent LPS molecules [1,2]. This bridging mechanism is vital for neutralizing electrostatic repulsion between the negatively charged LPS molecules, thereby stabilizing the outer membrane and maintaining its role as a robust permeability barrier against toxic substances [2,3]. These binding sites are the primary pharmacological targets for polymyxin antibiotics, such as colistin and polymyxin B [1,4]. Polymyxins act as cationic detergents that competitively displace the divalent cations from the phosphate groups, leading to the destabilization of the outer membrane, increased permeability, and eventual bacterial cell death [1,4]. Understanding these binding sites is also crucial for addressing antibiotic resistance, as many bacteria modify their lipid A phosphate groups to reduce their negative charge and evade drug binding [5].

Other names
Lipid A phosphate groupsLPS divalent cation binding sitesLipopolysaccharide phosphate moietiesDivalent cation bridges in Gram-negative outer membrane
02

Mechanism of action

Competitive displacement of divalent cations (magnesium and calcium) from the phosphate groups of lipid A, leading to the destabilization of the lipopolysaccharide layer, increased membrane permeability, and eventual cell lysis [1, 4].

03

Biological functions

Membrane stabilizationPermeability barrier maintenanceStructural integrity of the bacterial cell envelopeOther
04

Disease associations

Gram-negative bacterial infectionSepsisMultidrug-resistant bacterial infectionsInfection
05

Safety considerations

NephrotoxicityNeurotoxicityDevelopment of bacterial resistance via lipid A modification (e.g., mcr-1 gene)
06

Interacting drugs

Polymyxin B

3 more in the full profile.

07

Biomarkers

Lipopolysaccharide (LPS) levelsBacterial loadProcalcitonin

Beyond the preview

Go deeper on Lipid A phosphate group divalent cation binding site.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipid A phosphate group divalent cation binding site.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call